Enzyme immunoassay of urinary mevalonic acid and its clinical application

Clinical Chemistry

Volumn 44, Issue 10, 1998, Pages 2152-2157

  Hiramatsu, Makoto ^a   Hayashi, Akio ^a   Hidaka, Hideki ^b   Ueshima, Hirotsugu ^b   Kanno, Takashi ^c  

^a ONO PHARMACEUTICAL CO   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEVALONIC ACID; MONOCLONAL ANTIBODY; PRAVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; ENZYME IMMUNOASSAY; LIPID ANALYSIS; NONHUMAN; RAT; STREPTOZOCIN DIABETES; URINALYSIS; URINARY EXCRETION; URINE LEVEL;

ANIMALIA;

EID: 0031693955     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.10.2152     Document Type: Article

References (23)

1. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EH Jr, Alberts AW, et al. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Investig 1984;74:795-804.
2. Kopito RR, Weinstock SB, Freed LE, Murray DM, Brunengraber H. Metabolism of plasma mevalonate in rats and humans. J Lipid Res 1982;23:577-83.
3. Puppo MD, Cighetti G, Kienle MG, De Angelis L. Measurement of mevalonate in human plasma and urine by multiple selected ion monitoring. Biomed Environ Mass Spectrom 1989;18:174-6.
4. Hoffmann GF, Sweetman L, Bremer HJ, Hunnemann DH, Hyánek J, Kozich V, et al. Facts and artifacts in mevalonic aciduria: development of a stable isotope dilution GCMS assay for mevalonic acid and its application to physiological fluids, tissue samples, prenatal diagnosis and carrier detection. Clin Chim Acta 1991;198: 209-28.
5. Yoshida T, Honda A, Tanaka N, Matsuzaki Y, He B, Osuga T, et al. Simultaneous determination of mevalonate and 7α-hydroxycholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid biosynthesis. J Chromatogr 1993;613:185-93.
6. Siavoshian S, Simoneau C, Maugeais P, Marks L, Rodary L, Gardette J. Krempf M. Measurement of mevalonic acid in human urine by bench top gas chromatography-mass spectrometry. Clin Chim Acta 1995;243:129-36.
7. Lindenthal B, Von Bergmann K. Determination of urinary mevalonic acid using isotope dilution technique. Biol Mass Spectrom 1994;23:445-50.
8. Popják G, Boehm G, Parker TS, Edmond J, Edwards PA, Fogelman AM. Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man. J Lipid Res 1979;20:716-28.
9. Hiramatsu M, Hayashi A, Hamanaka N, Sugiyama M, Shimizu H, Kanno T. Enzyme immunoassay of human urinary mevalonic acid using highly specific monoclonal antibody. Rinsyo Kagaku 1995; 24:94-100.
10. Pappu AS, Illingworth DR, Bacon S. Reduction in plasma low-density-lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism 1989;38:542-9.
11. Beil UF, Beisiegel U, Schrameyer-Wernecke A, Ditschuneit HH, Stange EF, Echardt HG, Greten H. Lovastatin versus bezafibrate: effect on lipoproteins and urinary mevalonate. Atherosclerosis 1992;97:49-57.
12. Gleeson JM, Hejazi JS, Kwong L, Chan IF, Le T, Alberts AW, et al. Plasma apolipoprotein E, high density lipoprotein1 (HDL1) and urinary mevalonate excretion in pancreatectomized diabetic dogs: effect of insulin and lovastatin. Atherosclerosis 1990;84:1-12.
13. Kwong LK, Feingold KR, PericGolia L, Le T, Karkas JD, Alberts AW, Wilson DE. Intestinal and hepatic cholesterologenesis in hypercholesterolemic dyslipidemia of experimental diabetes in dogs. Diabetes 1991;40:1630-9.
14. Nakamura H, Nakagawa S. Influences of streptozotocin diabetes on intestinal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the rat. Diabetes 1977;26:439-44.
15. Young NL, Saudek CD, Crawford SA. Total hydroxymethylglutaryl CoA reductase activity in the small intestine and liver of insulin-deficient rats. J Lipid Res 1982;23:266-75.
16. Feingold KR, Wiley MH, MacRae G, Moser AH, Lear SR, Siperstein MD. The effect of diabetes mellitus on sterol synthesis in the diabetic rat. Diabetes 1982;31:388-95.
17. Feingold KR, Lear SR, Moser AH. De novo cholesterol synthesis in three different animal models of diabetes. Diabetologia 1984;26: 234-9.
18. Bar-on H, Roheim PS, Eder HA. Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes. J Clin Investig 1976;57:714-21.
19. Hosoda H, Kawamura N, Nambara T. Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for cortisol. Chem Pharm Bull 1981;29:1969-74.
20. Yoshida Y, Okayama A, Mikawa K, Ueshima H, Kita Y, Fujita Y, et al. Dietary intake and its relationship to serum cholesterol concentrations among three Japanese populations in the early 1990s: INTERSALT II study in Japan. J Shiga Univ Med Sci 1998;13:63-79.
21. Kopito RR, Brunengraber H. (R)-Mevalonate excretion in human and rat urines. Proc Natl Acad Sci U S A 1980;77:5738-40.
22. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990;29:239-43.
23. Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13.